Stock Analysis, Dividends, Split History
IVTY / Invuity, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||84.26|
|Enterprise Value ($M)||94.57|
|Book Value ($M)||2.33|
|Book Value / Share||0.10|
|Price / Book||36.13|
|NCAV / Share||-0.23|
|Price / NCAV||-14.98|
|Common Stock Shares Outstanding||17,179,258|
|Common Shares Outstanding||17,204,000|
|Preferred Stock Shares Outstanding||0|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-1.41|
|Return on Assets (ROA)||-0.66|
|Return on Equity (ROE)||-1.16|
|Income Statement (mra) ($M)|
|Minimum Net Revenue Requirements Period1||40,488,151.00|
|Minimum Net Revenue Requirements Period2||42,248,214.00|
|Minimum Net Revenue Requirements Period3||46,574,986.00|
|Minimum Net Revenue Requirements Period4||50,000,000.00|
|Earnings Per Share Basic And Diluted||-2.34|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||-38.88|
|Cash from Investing||6.87|
|Cash from Financing||6.87|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1393020|
|SIC 3841 - Surgical and Medical Instruments and Apparatus|
Stock splits are used by Invuity, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...
Related News Stories
Good day, ladies and gentlemen, and welcome to the Q2 2018 Invuity, Inc., Earnings Conference Call. At this time, all participations are in a listen only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.
Invuity (IVTY - Free Report) just came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.
A secondary offering in March provided them some breathing room and the appointment of Scott Flora as Interim President and Chief Executive Officer was a solid step forward.
Chicago, IL – July 17, 2018 - Stocks in this week’s article GMS Inc. (GMS - Free Report) , Invuity Inc. (IVTY - Free Report) , Hi-Crush Partners LP (HCLP - Free Report) , Belden Inc (BDC - Free Report) and Hubbell Inc (HUBB - Free Report) . (7-0)
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The perception is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind investors’ inclination toward low P/E stocks. (3-0)
as of ET